🔎 Trials Near Me

Akèy › Lukemi lenfositè kwonik › Kalifòni › Mountain View

Etid klinik pou Lukemi lenfositè kwonik nan Mountain View, CA

7 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Ap rekriteFaz 1/2
  • Stanford Medicine, Palo Alto · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Ap rekriteFaz 3
  • Stanford Cancer Institute, Palo Alto · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ap rekriteFaz 3
  • Stanford Cancer Institute, Palo Alto · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06973187

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Ap rekriteFaz 3
  • Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ap rekriteFaz 2
  • Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto · 5 mi lwen
  • Stanford Cancer Center, Palo Alto · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou May 19, 2026 · NCT06588478

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ap rekriteFaz 2
  • Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Mar 25, 2026 · NCT05388006

Etid Lukemi lenfositè kwonik nan lòt vil

Lòt etid nan Mountain View

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.